title: [TKI therapy for CML].
authors.forename: Kazunori
authors.initials: K
authors.lastname: Ohnishi
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000097:blood; D001549:Benzamides; D000069439:Dasatinib; D016903:Drug Monitoring; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics; D058990:Molecular Targeted Therapy; D010879:Piperazines / Q000008:administration & dosage* / Q000097:blood; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000008:administration & dosage* / Q000097:blood; D016032:Randomized Controlled Trials as Topic; D013844:Thiazoles
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; C498826:nilotinib; D000069439:Dasatinib